deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT02659020

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (ANNOUNCE 2)

A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

Sponsor: Eli Lilly and Company

Conditions Soft Tissue Sarcoma
Interventions Docetaxel Gemcitabine Olaratumab Placebo
Updated 29 times since 2017 Last updated: Apr 15, 2022 Started: Mar 1, 2016 Primary completion: Jul 28, 2020 Completion: Apr 27, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Soft Tissue Sarcoma and is currently completed. Eli Lilly and Company leads this study, which shows 29 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jul 2019 · 7 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

29 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Nov 2021 — Jun 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 24 earlier versions

  1. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2018 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  17. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  18. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  19. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  20. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  21. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  22. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1_PHASE2

  23. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Atlanta, United States , Aurora, United States , Bad Saarow, Germany , Baltimore, United States , Barcelona, Spain , Bebbington, United Kingdom , Berlin, Germany , Bordeaux, France , Boston, United States and 35 more locations